Credit Suisse Starts PTC Therapeutics (PTCT) at Outperform, $36 PT

Credit Suisse initiates coverage on PTC Therapeutics (NASDAQ: PTCT) with a Outperform rating and a price target of $36.00.

Analyst Alethia Young commented, "We are initiating coverage of PTC Therapeutics with an Outperform rating and a $36 target price. Much of the pipeline remains a free call option, including cystic fibrosis and SMA. We think that there is still a shot for approval in the US with its Ph2 and Ph3 dataset. At these levels, key focus is on whether the company remains on the EU/ROW market, and we think that it's likely."

For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.

Shares of PTC Therapeutics closed at $24.51 yesterday.

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'